INNOCAN PHARMA CORPO

INNO
Delayed Quote. Delayed  - 09/24 03:59:56 pm
1CAD +1.01%
Valuation
Fiscal Period: December 2019 2020
Capitalization1 17,749,1
Entreprise Value (EV)2 15,846,8
P/E ratio -4,45x-4,28x
Yield --
Capitalization / Revenue -6 132 126 693x
EV / Revenue -5 844 626 693x
EV / EBITDA -5 307 992x-9 980 152x
Price to Book 12,5x-13,7x
Nbr of stocks (in thousands) 143 866186 523
Reference price (USD) 0,120,26
Announcement Date 03/31/202103/31/2021
1 CAD in Million
2 USD in Million
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales -0,01
EBITDA -2,98-4,69
Operating profit (EBIT)1 -3,00-4,73
Operating Margin --59 063%
Pre-Tax Profit (EBT)1 -3,34-9,95
Net income1 -3,34-9,95
Net margin --124 413%
EPS2 -0,03-0,06
Dividend per Share --
Announcement Date 03/31/202103/31/2021
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 --
Net Cash position1 1,902,30
Leverage (Debt / EBITDA) 0,64x0,49x
Free Cash Flow -0,972,99
ROE (Net Profit / Equities) -433%907%
Shareholders' equity1 0,77-1,10
ROA (Net Profit / Asset) -116%-85,4%
Assets1 2,8811,7
Book Value Per Share2 0,01-0,02
Cash Flow per Share2 0,010,01
Capex1 0,01-
Capex / Sales --
Announcement Date 03/31/202103/31/2021
Previous period Next period
1 USD in Million
2 USD
EPS & Dividend